Smith & Nephew rewarded for swift action in knee recall
This article was originally published in Clinica
Executive Summary
Smith & Nephew is keen to minimise the significance of its US Oxinium knee implant recall, and by the look of its share price, investors at least are inclined to give it the benefit of the doubt. Its stock price slipped by less than 2% after it announced the voluntary recall of a limited number of cement-free knee replacements on September 17, and the following day the shares regained most of the lost ground.